Literature DB >> 21703177

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

Alexander J Thompson1, Paul J Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mingfu Zhu, Qianqian Zhu, Thomas J Urban, Keyur Patel, Hans L Tillmann, Susanna Naggie, Nezam H Afdhal, Ira M Jacobson, Rafael Esteban, Fred Poordad, Eric J Lawitz, Jonathan McCone, Mitchell L Shiffman, Greg W Galler, John W King, Paul Y Kwo, Kevin V Shianna, Stephanie Noviello, Lisa D Pedicone, Clifford A Brass, Janice K Albrecht, Mark S Sulkowski, David B Goldstein, John G McHutchison, Andrew J Muir.   

Abstract

BACKGROUND & AIMS: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia.
METHODS: 1604/3070 patients in the IDEAL study consented to genetic testing. Trial inclusion criteria included a platelet (Pl) count ≥80×10(9)/L and an absolute neutrophil count (ANC) ≥1500/mm(3). Samples were genotyped using the Illumina Human610-quad BeadChip. The primary analyses focused on the genetic determinants of quantitative change in cell counts (Pl, ANC, lymphocytes, monocytes, eosinophils, and basophils) at week 4 in patients >80% adherent to therapy (n=1294).
RESULTS: 6 SNPs on chromosome 20 were positively associated with Pl reduction (top SNP rs965469, p=10(-10)). These tag SNPs are in high linkage disequilibrium with 2 functional variants in the ITPA gene, rs1127354 and rs7270101, that cause ITPase deficiency and protect against ribavirin (RBV)-induced hemolytic anemia (HA). rs1127354 and rs7270101 showed strong independent associations with Pl reduction (p=10(-12), p=10(-7)) and entirely explained the genome-wide significant associations. We believe this is an example of an indirect genetic association due to a reactive thrombocytosis to RBV-induced anemia: Hb decline was inversely correlated with Pl reduction (r=-0.28, p=10(-17)) and Hb change largely attenuated the association between the ITPA variants and Pl reduction in regression models. No common genetic variants were associated with pegIFN-induced neutropenia or leucopenia.
CONCLUSIONS: Two ITPA variants were associated with thrombocytopenia; this was largely explained by a thrombocytotic response to RBV-induced HA attenuating IFN-related thrombocytopenia. No genetic determinants of pegIFN-induced neutropenia were identified.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703177      PMCID: PMC3634361          DOI: 10.1016/j.jhep.2011.04.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  34 in total

1.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Authors:  Jacques Fellay; Alexander J Thompson; Dongliang Ge; Curtis E Gumbs; Thomas J Urban; Kevin V Shianna; Latasha D Little; Ping Qiu; Arthur H Bertelsen; Mark Watson; Amelia Warner; Andrew J Muir; Clifford Brass; Janice Albrecht; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2010-02-21       Impact factor: 49.962

2.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

Review 3.  The global burden of hepatitis C.

Authors:  Daniel Lavanchy
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

4.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

5.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

6.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

7.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo.

Authors:  Caroline Sommereyns; Sophie Paul; Peter Staeheli; Thomas Michiels
Journal:  PLoS Pathog       Date:  2008-03-14       Impact factor: 6.823

9.  Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene.

Authors:  David Reich; Michael A Nalls; W H Linda Kao; Ermeg L Akylbekova; Arti Tandon; Nick Patterson; James Mullikin; Wen-Chi Hsueh; Ching-Yu Cheng; Josef Coresh; Eric Boerwinkle; Man Li; Alicja Waliszewska; Julie Neubauer; Rongling Li; Tennille S Leak; Lynette Ekunwe; Joe C Files; Cheryl L Hardy; Joseph M Zmuda; Herman A Taylor; Elad Ziv; Tamara B Harris; James G Wilson
Journal:  PLoS Genet       Date:  2009-01-30       Impact factor: 5.917

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  16 in total

1.  Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype.

Authors:  Hwalih Han; Mazen Noureddin; Michael Witthaus; Yoon J Park; Jay H Hoofnagle; T Jake Liang; Yaron Rotman
Journal:  J Hepatol       Date:  2013-07-10       Impact factor: 25.083

Review 2.  Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.

Authors:  Emmanuel Peprah; Huichun Xu; Fasil Tekola-Ayele; Charmaine D Royal
Journal:  Public Health Genomics       Date:  2014-11-26       Impact factor: 2.000

3.  Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C.

Authors:  Etsuko Iio; Kentaro Matsuura; Nao Nishida; Shinya Maekawa; Nobuyuki Enomoto; Mina Nakagawa; Naoya Sakamoto; Hiroshi Yatsuhashi; Masayuki Kurosaki; Namiki Izumi; Yoichi Hiasa; Naohiko Masaki; Tatsuya Ide; Keisuke Hino; Akihiro Tamori; Masao Honda; Shuichi Kaneko; Satoshi Mochida; Hideyuki Nomura; Shuhei Nishiguchi; Chiaki Okuse; Yoshito Itoh; Hitoshi Yoshiji; Isao Sakaida; Kazuhide Yamamoto; Hisayoshi Watanabe; Shuhei Hige; Akihiro Matsumoto; Eiji Tanaka; Katsushi Tokunaga; Yasuhito Tanaka
Journal:  Hum Genet       Date:  2014-12-17       Impact factor: 4.132

4.  Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.

Authors:  Sabela Lens; Jose L Calleja; Ana Campillo; Jose A Carrión; Teresa Broquetas; Christie Perello; Juan de la Revilla; Zoe Mariño; María-Carlota Londoño; Jose M Sánchez-Tapias; Álvaro Urbano-Ispizua; Xavier Forns
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

5.  Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.

Authors:  Tatsuo Miyamura; Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Xia Jiang; Makoto Arai; Keiichi Fujiwara; Fumio Imazeki; Osamu Yokosuka
Journal:  Viruses       Date:  2012-08-14       Impact factor: 5.048

Review 6.  Clinical utility of pharmacogenomics in the management of hepatitis C.

Authors:  Julieta Trinks; María Laura Hulaniuk; María Ana Redal; Diego Flichman
Journal:  Pharmgenomics Pers Med       Date:  2014-10-20

Review 7.  Pharmacogenomics of hepatitis C infections: personalizing therapy.

Authors:  David R Booth; Golo Ahlenstiel; Jacob George
Journal:  Genome Med       Date:  2012-12-26       Impact factor: 11.117

8.  Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.

Authors:  Francesc Vidal; Miguel López-Dupla; Montserrat Laguno; Sergi Veloso; Josep Mallolas; Javier Murillas; Carmen Cifuentes; Lluis Gallart; Teresa Auguet; Gloria Sampériz; Antoni Payeras; Pilar Hernandez; Mireia Arnedo; Josep Ma Gatell; Cristóbal Richart
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

9.  ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.

Authors:  Raoel Maan; Adriaan J van der Meer; Willem Pieter Brouwer; Elisabeth P C Plompen; Milan J Sonneveld; Robert Roomer; Annemiek A van der Eijk; Zwier M A Groothuismink; Bettina E Hansen; Bart J Veldt; Harry L A Janssen; Andre Boonstra; Robert J de Knegt
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

10.  Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.

Authors:  Jow Jyh Hwang; Ching Chu Lo; Chien Hung Lin; Hsu Sheng Cheng; I Wen Hung; Wan Ju Tsai; Chien Hui Hung
Journal:  Gut Liver       Date:  2015-03       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.